Search

Your search keyword '"Fontana, Valeria"' showing total 22 results
Start Over Author "Fontana, Valeria"
22 results on '"Fontana, Valeria"'

1. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG)

Author

Gronchi, Alessandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin Broto, Javier, additional, Lopez Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean-Yves, additional, Tendero, Oscar, additional, Diaz Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Pizzamiglio, Sara, additional, Verderio, Paolo, additional, Fontana, Valeria, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Sanfilippo, Roberta, additional, Bianchi, Giuseppe, additional, Bertuzzi, Alexia, additional, Morosi, Carlo, additional, Pasquali, Sandro, additional, Stacchiotti, Silvia, additional, Bagué, Silvia, additional, Coindre, Jean Michel, additional, Miceli, Rosalba, additional, Dei Tos, Angelo Paolo, additional, and Casali, Paolo Giovanni, additional

Published
2024
Full Text
View/download PDF

2. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study

Author

Lambertini, Matteo, Fontana, Valeria, Massarotti, Claudia, Poggio, Francesca, Dellepiane, Chiara, Iacono, Giuseppina, Abate, Annalisa, Miglietta, Loredana, Ferreccio, Chiara, Pescio, Maria Carolina, Conte, Benedetta, Blondeaux, Eva, Bighin, Claudia, D'Alonzo, Alessia, Vaglica, Marina, Zanardi, Elisa, Boccardo, Francesco, Ballestrero, Alberto, Anserini, Paola, and Del Mastro, Lucia

Published
2018
Full Text
View/download PDF

3. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Author

Gronchi, Alessandro, Ferrari, Stefano, Quagliuolo, Vittorio, Broto, Javier Martin, Pousa, Antonio Lopez, Grignani, Giovanni, Basso, Umberto, Blay, Jean-Yves, Tendero, Oscar, Beveridge, Robert Diaz, Ferraresi, Virginia, Lugowska, Iwona, Merlo, Domenico Franco, Fontana, Valeria, Marchesi, Emanuela, Donati, Davide Maria, Palassini, Elena, Palmerini, Emanuela, De Sanctis, Rita, Morosi, Carlo, Stacchiotti, Silvia, Bagué, Silvia, Coindre, Jean Michelle, Dei Tos, Angelo Paolo, Picci, Piero, Bruzzi, Paolo, and Casali, Paolo Giovanni

Published
2017
Full Text
View/download PDF

4. REGIONE VI

Author

Fogagnolo, Stefania, Carrano, Paola, Negroni, Alessandra, Fontana, Sergio, Piccirilli, Simona, Guspini, Liliana, Mazzotta, Bartolomeo, Adinolfi, Gloria, Carmagnola, Rodolfo, Festuccia, Silvia, Fontana, Valeria, Tanganelli, Roberta, and Pischedda, Eugenio

Published
2012

5. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial

Author

PharmaMar, European Commission, Pasquali, Sandro [0000-0003-4815-6293], Palmerini, Emanuela [0000-0003-3406-6705], Grignani, Giovanni [0000-0001-5515-569X], Brunello, Antonella [0000-0003-2583-5226], Blay, Jean-Yves [0000-0001-7190-120X], Stacchiotti, Silvia [0000-0002-1742-8666], Pasquali, Sandro, Palmerini, Emanuela, Quagliuolo, Vittorio, Martín-Broto, Javier, López-Pousa, Antonio, Grignani, Giovanni, Brunello, Antonella, Blay, Jean-Yves, Tendero, Oscar, Díaz-Beveridge, Robert, Ferraresi, Virginia, Lugowska, Iwona, Infante, Gabriele, Braglia, Luca, Merlo, Domenico Franco, Fontana, Valeria, Marchesi, Emanuela, Donati, Davide María, Palassini, Elena, Bianchi, Giuseppe, Marrari, Andrea, Morosi, Carlo, Stacchiotti, Silvia, Bagué, Silvia, Coindre, Jean Michel, Dei Tos, Angelo Paolo, Picci, Piero, Bruzzi, Paolo, Miceli, Rosalba, Casali, Paolo Giovanni, Gronchi, Alessandro, PharmaMar, European Commission, Pasquali, Sandro [0000-0003-4815-6293], Palmerini, Emanuela [0000-0003-3406-6705], Grignani, Giovanni [0000-0001-5515-569X], Brunello, Antonella [0000-0003-2583-5226], Blay, Jean-Yves [0000-0001-7190-120X], Stacchiotti, Silvia [0000-0002-1742-8666], Pasquali, Sandro, Palmerini, Emanuela, Quagliuolo, Vittorio, Martín-Broto, Javier, López-Pousa, Antonio, Grignani, Giovanni, Brunello, Antonella, Blay, Jean-Yves, Tendero, Oscar, Díaz-Beveridge, Robert, Ferraresi, Virginia, Lugowska, Iwona, Infante, Gabriele, Braglia, Luca, Merlo, Domenico Franco, Fontana, Valeria, Marchesi, Emanuela, Donati, Davide María, Palassini, Elena, Bianchi, Giuseppe, Marrari, Andrea, Morosi, Carlo, Stacchiotti, Silvia, Bagué, Silvia, Coindre, Jean Michel, Dei Tos, Angelo Paolo, Picci, Piero, Bruzzi, Paolo, Miceli, Rosalba, Casali, Paolo Giovanni, and Gronchi, Alessandro

Abstract

[Background] The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood. This study investigated the benefit of neoadjuvant chemotherapy according to prognostic stratification based on the Sarculator nomogram for STS., [Methods] This study analyzed data from ISG-STS 1001, a randomized study that tested 3 cycles of neoadjuvant anthracycline plus ifosfamide (AI) or histology-tailored (HT) chemotherapy in adult patients with STS. The 10-year predicted overall survival (pr-OS) was estimated with the Sarculator and was stratified into higher (10-year pr-OS < 60%) and lower risk subgroups (10-year pr-OS ≥ 60%)., [Results] The median pr-OS was 0.63 (interquartile range [IQR], 0.51-0.72) for the entire study population, 0.62 (IQR, 0.51-0.70) for the AI arm, and 0.64 (IQR, 0.51-0.73) for the HT arm. Three- and 5-year overall survival (OS) were 0.86 (95% confidence interval [CI], 0.82-0.93) and 0.81 (95% CI, 0.71-0.86) in lower risk patients and 0.69 (95% CI, 0.70-0.85) and 0.59 (95% CI, 0.51-0.72) in the higher risk patients (log-rank test, P = .004). In higher risk patients, the 3- and 5-year Sarculator-predicted and study-observed OS rates were 0.68 and 0.58, respectively, and 0.85 and 0.66, respectively, in the AI arm (P = .04); the corresponding figures in the HT arm were 0.69 and 0.60, respectively, and 0.69 and 0.55, respectively (P > .99). In lower risk patients, the 3- and 5-year Sarculator-predicted and study-observed OS rates were 0.85 and 0.80, respectively, and 0.89 and 0.82, respectively, in the AI arm (P = .507); the corresponding figures in the HT arm were 0.87 and 0.81, respectively, and 0.86 and 0.74, respectively (P = .105)., [Conclusions] High-risk patients treated with AI performed better than predicted, and this adds to the evidence for the efficacy of neoadjuvant AI in STS.

Published
2022

6. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

Author

Gronchi, Alessandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin Broto, Javier, additional, Lopez-Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean-Yves, additional, Diaz Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Pizzamiglio, Sara, additional, Verderio, Paolo, additional, Fontana, Valeria, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Stacchiotti, Silvia, additional, Miceli, Rosalba, additional, Dei Tos, Angelo Paolo, additional, and Casali, Paolo Giovanni, additional

Published
2022
Full Text
View/download PDF

7. Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial

Author

Pasquali, Sandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin‐Broto, Javier, additional, Lopez‐Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean‐Yves, additional, Tendero, Oscar, additional, Diaz‐Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Infante, Gabriele, additional, Braglia, Luca, additional, Merlo, Domenico Franco, additional, Fontana, Valeria, additional, Marchesi, Emanuela, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Bianchi, Giuseppe, additional, Marrari, Andrea, additional, Morosi, Carlo, additional, Stacchiotti, Silvia, additional, Bagué, Silvia, additional, Coindre, Jean Michel, additional, Dei Tos, Angelo Paolo, additional, Picci, Piero, additional, Bruzzi, Paolo, additional, Miceli, Rosalba, additional, Casali, Paolo Giovanni, additional, Gronchi, Alessandro, additional, Dani, Carla, additional, Villa, Chiara, additional, Messina, Antonella, additional, Rusi, Lorella, additional, Nuzzo, Anna Maria, additional, Nuzzo, Carmen, additional, De Paoli, Antonino, additional, Buonadonna, Angela, additional, Comandone, Alessandro, additional, Boglione, Antonella, additional, Livi, Lorenzo, additional, Greto, Daniela, additional, Riva, Nada, additional, Monti, Manuela, additional, Pennacchioli, Elisabetta, additional, De Pas, Tommaso, additional, Ippolito, Vincenzo, additional, Ledesma, Patrico, additional, Redondo, Andres, additional, Valverde, Claudia, additional, Bratos, Raquel, additional, Cruz, Josefina, additional, Martinez Trufero, Javier, additional, Cubedo, Ricardo, additional, Sevilla, Isabel, additional, Luna, Pablo, additional, Lopez, Rafael, additional, Sancho, Pilar, additional, Bally, Olivia, additional, Brahmi, Mehdi, additional, Ray‐Coquard, Isabelle, additional, Cassier, Philippe, additional, Marques, Nathalie, additional, Tassy, Luis, additional, Boudou‐Rouquette, Pascaline, additional, Tlemsani, Camille, additional, Alexandre, Jerome, additional, Goldwasser, Francois, additional, Bompas, Emmanuelle, additional, Rolland, Frederic, additional, Perrin, Christophe, additional, Talarmin, Marie, additional, Italiano, Antoine, additional, Toulmonde, Maud, additional, Laramas, Mathieu, additional, Bay, Jacques‐Olivier, additional, Dubray‐Longeras, Pascale, additional, and Rutkowski, Piotr, additional

Published
2021
Full Text
View/download PDF

8. The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer

Author

Blondeaux, Eva, primary, Massarotti, Claudia, additional, Fontana, Valeria, additional, Poggio, Francesca, additional, Arecco, Luca, additional, Fregatti, Piero, additional, Bighin, Claudia, additional, Giannubilo, Irene, additional, Ruelle, Tommaso, additional, Razeti, Maria Grazia, additional, Boni, Luca, additional, Anserini, Paola, additional, Del Mastro, Lucia, additional, and Lambertini, Matteo, additional

Published
2021
Full Text
View/download PDF

9. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Author

Gronchi, Alessandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin Broto, Javier, additional, Lopez Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean-Yves, additional, Tendero, Oscar, additional, Diaz Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Merlo, Domenico Franco, additional, Fontana, Valeria, additional, Marchesi, Emanuela, additional, Braglia, Luca, additional, Donati, Davide Maria, additional, Palassini, Elena, additional, Bianchi, Giuseppe, additional, Marrari, Andrea, additional, Morosi, Carlo, additional, Stacchiotti, Silvia, additional, Bagué, Silvia, additional, Coindre, Jean Michel, additional, Dei Tos, Angelo Paolo, additional, Picci, Piero, additional, Bruzzi, Paolo, additional, and Casali, Paolo Giovanni, additional

Published
2020
Full Text
View/download PDF

10. Prognostic role of % changes in longest tumor diameter (LTD) in localized high-risk soft tissue sarcoma (STS) treated with neoadjuvant chemotherapy in a randomized clinical trial.

Author

Stacchiotti, Silvia, primary, Morosi, Carlo, additional, Braglia, Luca, additional, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin Broto, Javier, additional, Lopez-Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean-Yves, additional, Tendero, Oscar, additional, Diaz Beveridge, Robert, additional, Lugowska, Iwona, additional, Fontana, Valeria, additional, Marchesi, Emanuela, additional, Palassini, Elena, additional, Bruzzi, Paolo, additional, Merlo, Franco Domenico, additional, Casali, Paolo Giovanni, additional, and Gronchi, Alessandro, additional

Published
2020
Full Text
View/download PDF

11. RANGER: Radars and Early Warning Technologies for Long Distance Maritime Surveillance

Author

Karagiannidis Lazaros, Dres Dimitrios, Protopapadakis Eftychios, Lamole Frédéric, Jacquin François, Rigal Gilles, Ouzounoglou Eleftherios, Katsaros Dimitris, Karalis Alexandros, Pierno Luigi, Mastroeni Carmelo, Evangelista Marco, Fontana Valeria, Gaglione Domenico, Soldi Giovanni, Braca Paolo, Sarlio-Siintola Sari, Sdongos Evangelos, and Amditis Angelos

Subjects
machine learning, maritime surveillance, Over-The-Horizon (OTH) Radar, ethics compliance, early warning system
Abstract

In this paper, we present a high-level view of RANGER, a novel platform that combines innovative radar technologies with cutting edge technological solutions for early warning, in view of delivering a surveillance platform offering detection, recognition, identification and tracking of suspicious vessels, i.e. capabilities that exceed those of current radar systems. The RANGER platform consists of two radar technologies, a novel Over-The-Horizon (OTH) Radar combined with a Multiple- input and Multiple-output Radar (MIMO) implemented exploiting the latest photonics advancements, a Uniform Communication Gateway (UCG) for seamless, secure and interoperable integration of radars and legacy systems, an Early Warning System (EWS) exploiting data fusion and deep and adaptable machine learning schemes able to automatically detect radar targets and produce early warnings, an Advanced User Interface (AUI) for visualization of the maritime operational picture, and a Common Information Sharing Environment (CISE) gateway adapter for sharing information with the CISE network. The RANGER system aims at significantly progressing the accuracy and long distance detection, identification and recognition rates as well as improving the provision of early warnings and alerts related to maritime operations, thus drastically improving the response and intervention capacity of related European services.

Published
2019
Full Text
View/download PDF

12. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Author

European Commission, PharmaMar, Gronchi, Alesandro, Palmerini, Emanuela, Quagliuolo, V., Martín-Broto, Javier, López-Pousa, Antonio, Grignani, Giovanni, Brunello, Antonella, Blay, Jean-Yves, Tendero, Óscar, Díaz-Beveridge, Robert, Ferraresi, Virginia, Lugowska, Iwona, Merlo, Domenico Franco, Fontana, Valeria, Marchesi, Emanuela, Braglia, Luca, Donati, Davide María, Palassini, Elena, Bianchi, Giuseppe, Marrari, Andrea, Morosi, Carlo, Stacchiotti, Silvia, Bagué, Silvia, Coindre, Jean-Michel, Dei Tos, Angelo Paolo, Picci, Piero, Bruzzi, Paolo, Casali, Paolo G., European Commission, PharmaMar, Gronchi, Alesandro, Palmerini, Emanuela, Quagliuolo, V., Martín-Broto, Javier, López-Pousa, Antonio, Grignani, Giovanni, Brunello, Antonella, Blay, Jean-Yves, Tendero, Óscar, Díaz-Beveridge, Robert, Ferraresi, Virginia, Lugowska, Iwona, Merlo, Domenico Franco, Fontana, Valeria, Marchesi, Emanuela, Braglia, Luca, Donati, Davide María, Palassini, Elena, Bianchi, Giuseppe, Marrari, Andrea, Morosi, Carlo, Stacchiotti, Silvia, Bagué, Silvia, Coindre, Jean-Michel, Dei Tos, Angelo Paolo, Picci, Piero, Bruzzi, Paolo, and Casali, Paolo G.

Abstract

[Purpose] To determine whether the administration of histology-tailored neoadjuvant chemotherapy (HT) was superior to the administration of standard anthracycline plus ifosfamide neoadjuvant chemotherapy (A+I) in high-risk soft tissue sarcoma (STS) of an extremity or the trunk wall., [Patients and methods] This was a randomized, open-label, phase III trial. Patients had localized high-risk STS (grade 3; size, ≥ 5 cm) of an extremity or trunk wall, belonging to one of the following five histologic subtypes: high-grade myxoid liposarcoma (HG-MLPS); leiomyosarcoma (LMS), synovial sarcoma (SS), malignant peripheral nerve sheath tumor (MPNST), and undifferentiated pleomorphic sarcoma (UPS). Patients were randomly assigned in a 1:1 ratio to receive three cycles of A+I or HT. The HT regimens were as follows: trabectedin in HG-MLPS; gemcitabine plus dacarbazine in LMS; high-dose prolonged-infusion ifosfamide in SS; etoposide plus ifosfamide in MPNST; and gemcitabine plus docetaxel in UPS. Primary and secondary end points were disease-free survival (DFS) and overall survival (OS), estimated using the Kaplan-Meier method and compared using Cox models adjusted for treatment and stratification factors. The study is registered at ClinicalTrials.gov (identifier NCT01710176)., [Results] Between May 2011 and May 2016, 287 patients (UPS: n = 97 [33.8%]; HG-MLPS: n = 65 [22.6%]; SS: n = 70 [24.4%]; MPNST: n = 27 [9.4%]; and LMS: n = 28 [9.8%]) were randomly assigned to either A+I or HT. At the final analysis, with a median follow-up of 52 months, the projected DFS and OS probabilities were 0.55 and 0.47 (log-rank P = .323) and 0.76 and 0.66 (log-rank P = .018) at 60 months in the A+I arm and HT arm, respectively. No treatment-related deaths were observed., [Conclusions] In a population of patients with localized high-risk STS, HT was not associated with a better DFS or OS, suggesting that A+I should remain the regimen to choose whenever neoadjuvant chemotherapy is used in patients with high-risk STS.

Published
2020

13. Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial.

Author

Pasquali, Sandro, Palmerini, Emanuela, Quagliuolo, Vittorio, Martin‐Broto, Javier, Lopez‐Pousa, Antonio, Grignani, Giovanni, Brunello, Antonella, Blay, Jean‐Yves, Tendero, Oscar, Diaz‐Beveridge, Robert, Ferraresi, Virginia, Lugowska, Iwona, Infante, Gabriele, Braglia, Luca, Merlo, Domenico Franco, Fontana, Valeria, Marchesi, Emanuela, Donati, Davide Maria, Palassini, Elena, and Bianchi, Giuseppe

Subjects
SARCOMA, NEOADJUVANT chemotherapy, ADJUVANT chemotherapy, RISK assessment, LOG-rank test
Abstract

Background: The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood. This study investigated the benefit of neoadjuvant chemotherapy according to prognostic stratification based on the Sarculator nomogram for STS. Methods: This study analyzed data from ISG‐STS 1001, a randomized study that tested 3 cycles of neoadjuvant anthracycline plus ifosfamide (AI) or histology‐tailored (HT) chemotherapy in adult patients with STS. The 10‐year predicted overall survival (pr‐OS) was estimated with the Sarculator and was stratified into higher (10‐year pr‐OS < 60%) and lower risk subgroups (10‐year pr‐OS ≥ 60%). Results: The median pr‐OS was 0.63 (interquartile range [IQR], 0.51‐0.72) for the entire study population, 0.62 (IQR, 0.51‐0.70) for the AI arm, and 0.64 (IQR, 0.51‐0.73) for the HT arm. Three‐ and 5‐year overall survival (OS) were 0.86 (95% confidence interval [CI], 0.82‐0.93) and 0.81 (95% CI, 0.71‐0.86) in lower risk patients and 0.69 (95% CI, 0.70‐0.85) and 0.59 (95% CI, 0.51‐0.72) in the higher risk patients (log‐rank test, P =.004). In higher risk patients, the 3‐ and 5‐year Sarculator‐predicted and study‐observed OS rates were 0.68 and 0.58, respectively, and 0.85 and 0.66, respectively, in the AI arm (P =.04); the corresponding figures in the HT arm were 0.69 and 0.60, respectively, and 0.69 and 0.55, respectively (P >.99). In lower risk patients, the 3‐ and 5‐year Sarculator‐predicted and study‐observed OS rates were 0.85 and 0.80, respectively, and 0.89 and 0.82, respectively, in the AI arm (P =.507); the corresponding figures in the HT arm were 0.87 and 0.81, respectively, and 0.86 and 0.74, respectively (P =.105). Conclusions: High‐risk patients treated with AI performed better than predicted, and this adds to the evidence for the efficacy of neoadjuvant AI in STS. Lay Summary: People affected by soft tissue sarcomas of the extremities and trunk wall are at some risk of developing metastasis after surgery.Preoperative or postoperative chemotherapy has been tested in clinical trials to reduce the chances of distant metastasis. However, study findings have not been conclusive.This study stratified the risk of metastasis for people affected by sarcomas who were included in a clinical trial testing neoadjuvant chemotherapy. Exploiting the prognostic nomogram Sarculator, it found a benefit for chemotherapy when the predicted risk, based on patient and tumor characteristics, was high. This analysis of the ISG‐STS 1001 trial, which compares anthracycline plus ifosfamide and histology‐tailored chemotherapy in 5 high‐risk soft tissue sarcomas of the extremities and trunk wall, supports the Sarculator nomogram for stratifying patient risk in clinical practice and in clinical trials that will investigate perioperative therapies for soft tissue sarcomas. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

Author

Gronchi, Alessandro, primary, Palmerini, Emanuela, additional, Quagliuolo, Vittorio, additional, Martin Broto, Javier, additional, Lopez Pousa, Antonio, additional, Grignani, Giovanni, additional, Brunello, Antonella, additional, Blay, Jean-Yves, additional, Diaz Beveridge, Robert, additional, Ferraresi, Virginia, additional, Lugowska, Iwona, additional, Merlo, Franco Domenico, additional, Fontana, Valeria, additional, Palassini, Elena, additional, Morosi, Carlo, additional, Stacchiotti, Silvia, additional, Dei Tos, Angelo Paolo, additional, Picci, Piero, additional, Bruzzi, Paolo, additional, and Casali, Paolo Giovanni, additional

Published
2019
Full Text
View/download PDF

15. The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients

Author

Lambertini, Matteo, primary, Anserini, Paola, additional, Fontana, Valeria, additional, Poggio, Francesca, additional, Iacono, Giuseppina, additional, Abate, Annalisa, additional, Levaggi, Alessia, additional, Miglietta, Loredana, additional, Bighin, Claudia, additional, Giraudi, Sara, additional, D’Alonzo, Alessia, additional, Blondeaux, Eva, additional, Buffi, Davide, additional, Campone, Francesco, additional, Merlo, Domenico F., additional, and Del Mastro, Lucia, additional

Published
2017
Full Text
View/download PDF

16. The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)

Author

Dellepiane, Chiara, Lambertini, Matteo, Fontana, Valeria, Poggio, Francesca, Blondeaux, Eva, Conte, Benedetta, D'Alonzo, Alessia, Vaglica, Marina, Bighin, Claudia, Iacono, Giuseppina, Abate, Annalisa, Pastorino, Simona, Pescio, Maria M.C., Anserini, Paola, Del Mastro, Lucia, Dellepiane, Chiara, Lambertini, Matteo, Fontana, Valeria, Poggio, Francesca, Blondeaux, Eva, Conte, Benedetta, D'Alonzo, Alessia, Vaglica, Marina, Bighin, Claudia, Iacono, Giuseppina, Abate, Annalisa, Pastorino, Simona, Pescio, Maria M.C., Anserini, Paola, and Del Mastro, Lucia

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

17. The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients

Author

Lambertini, Matteo, Giraudi, Sara, D'Alonzo, Alessia, Blondeaux, Eva, Buffi, Davide, Campone, Francesco, Merlo, Domenico Franco, Del Mastro, Lucia, Anserini, Paola, Fontana, Valeria, Poggio, Francesca, Iacono, Giuseppina, Abate, Annalisa, Levaggi, Alessia, Miglietta, Loredana, Bighin, Claudia, Lambertini, Matteo, Giraudi, Sara, D'Alonzo, Alessia, Blondeaux, Eva, Buffi, Davide, Campone, Francesco, Merlo, Domenico Franco, Del Mastro, Lucia, Anserini, Paola, Fontana, Valeria, Poggio, Francesca, Iacono, Giuseppina, Abate, Annalisa, Levaggi, Alessia, Miglietta, Loredana, and Bighin, Claudia

Abstract

Background: Fertility and pregnancy issues are of key importance for young breast cancer patients. Despite several advances in the field, there are still multiple unmet needs and barriers in discussing and dealing with these concerns. To address the significant challenges related to fertility and pregnancy issues, the PREgnancy and FERtility (PREFER) study was developed as a national comprehensive program aiming to optimize care and improve knowledge around these topics. Methods: The PREFER study is a prospective cohort study conducted across several Italian institution affiliated with the Gruppo Italiano Mammella (GIM) group evaluating patterns of care and clinical outcomes of young breast cancer patients dealing with fertility and pregnancy issues. It is composed of two distinctive studies: PREFER-FERTILITY and PREFER-PREGNANCY. The PREFER-FERTILITY study is enrolling premenopausal patients aged 18-45 years, diagnosed with non-metastatic breast cancer, who are candidates to (neo)adjuvant chemotherapy and not previously exposed to anticancer therapies. The primary objective is to obtain and centralize data about patients' preferences and choices towards the available fertility preserving procedures. The success and safety of these strategies and the hormonal changes during chemotherapy and study follow-up are secondary objectives. The PREFER-PREGNANCY study is enrolling survivors achieving a pregnancy after prior history of breast cancer and patients diagnosed with pregnancy-associated breast cancer (PABC). The primary objectives are to obtain and centralize data about the management and clinical outcomes of these women. Patients' survival outcomes, and the fetal, obstetrical and paediatric care of their children are secondary objectives. For both studies, the initial planned recruitment period is 5 years and patients will remain in active follow-up for up to 15 years. The PREFER-FERTILITY study was first activated in November 2012, and the PREFER-PREGNANCY study i, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

18. Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib

Author

Queirolo, Paola, primary, Spagnolo, Francesco, additional, Picasso, Virginia, additional, Spano, Laura, additional, Tanda, Enrica, additional, Fontana, Valeria, additional, Giorello, Laura, additional, Merlo, Domenico Franco, additional, Simeone, Ester, additional, Grimaldi, Antonio Maria, additional, Curvietto, Marcello, additional, Del Vecchio, Michele, additional, Bruzzi, Paolo, additional, and Ascierto, Paolo Antonio, additional

Published
2016
Full Text
View/download PDF

19. Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.

Author

Pasquali, Sandro, Collini, Paola, Romagosa, Cleofe, Coindre, Jean Michel, Pizzamiglio, Sara, Verderio, Paolo, Barisella, Marta, Palmerini, Emanuela, Quagliuolo, Vittorio, Martin Broto, Javier, Lopez-Pousa, Antonio, Grignani, Giovanni, Blay, Jean-Yves, Lugowska, Iwona A., Fontana, Valeria, Sbaraglia, Marta, Bague, Silvia, De Tos, Paolo, Casali, Paolo G, and Gronchi, Alessandro

Published
2023
Full Text
View/download PDF

20. A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.

Author

Palassini, Elena, Pizzamiglio, Sara, Palmerini, Emanuela, Quagliuolo, Vittorio, Martin Broto, Javier, Grignani, Giovanni, Brunello, Antonella, Blay, Jean-Yves, Tendero, Oscar, Beveridge, Robbie, Lopez Pousa, Antonio, Ferraresi, Virginia, Lugowska, Iwona, Fontana, Valeria, Bianchi, Giuseppe, Stacchiotti, Silvia, Dei Tos, Angelo Paolo, Verderio, Paolo, Casali, Paolo Giovanni, and Gronchi, Alessandro

Published
2023
Full Text
View/download PDF

21. Prospective observational study on fertility preservation in young early breast cancer patients: The PREFER (Pregnancy and Fertility) trial.

Author

Lambertini, Matteo, primary, Anserini, Paola, additional, Fontana, Valeria, additional, Abate, Annalisa, additional, Sozzi, Fausta, additional, Merlo, Franco, additional, Pronzato, Paolo, additional, Bighin, Claudia, additional, Levaggi, Alessia, additional, D'Alonzo, Alessia, additional, Giraudi, Sara, additional, Iacono, Giuseppina, additional, Miglietta, Loredana, additional, Poggio, Francesca, additional, and Del Mastro, Lucia, additional

Published
2013
Full Text
View/download PDF

22. The Postoperative Analgesic Efficacy of Preperitoneal Continuous Wound Infusion Compared to Epidural Continuous Infusion with Local Anesthetics After Colorectal Cancer Surgery

Author

Bertoglio, Sergio, primary, Fabiani, Fabio, additional, Negri, Pasquale De, additional, Corcione, Antonio, additional, Merlo, Domenico Franco, additional, Cafiero, Ferdinando, additional, Esposito, Clelia, additional, Belluco, Claudio, additional, Pertile, Davide, additional, Amodio, Riccardo, additional, Mannucci, Matilde, additional, Fontana, Valeria, additional, Cicco, Marcello De, additional, and Zappi, Lucia, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results